Hormone & Organ Health · Rx only

CJC-1295 / Ipamorelin, prescribed properly.

Skip the gray-market guesswork. A licensed clinician reviews your health history, a licensed U.S. pharmacy compounds your prescription, and a care team stays with you after it ships.

$256.50 / mo$285 as a single month · $684 per quarter

A licensed clinician reviews every request. If CJC-1295 / Ipamorelin fits your health history, they write your prescription and your pharmacy takes it from there.

Licensed U.S. providers Licensed U.S. pharmacy All 50 states + D.C.

Requires an online medical evaluation. Prescribed only when a licensed provider determines it's appropriate.

A licensed clinician in a consultation room
CJC-1295 / Ipamorelin vial and spec card
CJC-1295 / Ipamorelin · Rx only
1

Share your health history

CJC-1295 / Ipamorelin has its own online clinical questionnaire — your history, medications, and goals.

2

Your answers get a careful review

A clinician reads your history and takes the time to get it right before anything is prescribed.

3

Your pharmacy ships

Compounded for your prescription and shipped cold-chain, with care-team check-ins after.

The safe way to take CJC-1295 / Ipamorelin seriously

CJC-1295 / Ipamorelin is easy to find online and hard to trust there. Promise works the way medicine is supposed to work — a clinician decides, a licensed pharmacy fills, and someone stays accountable to you.

A real prescription

Prescribed for you specifically, after a real look at your health history — never pulled off a shelf.

A real pharmacy

Your prescription is compounded for you by a licensed U.S. pharmacy — not a mystery vial from an unregulated website.

Real oversight

Temperature-safe shipping, follow-up check-ins, and a care team that answers — before and after your medication arrives.

Product details
Form
Injectable vial (subcutaneous), 1.2 mg / 2 mg per mL
Supply
28-day supply
Pharmacy
Compounded by a licensed U.S. pharmacy
Availability
Ships to all 50 states + D.C.; not all treatments are available in every state

Two signals, one pulse

A GHRH analog and a ghrelin-receptor secretagogue act on different receptors on the same pituitary cells, which is the mechanistic reason the two are studied as a pair.

The pituitary stays in the loop

Release still runs through your own pituitary gland, so the feedback controls that govern growth hormone are not bypassed the way they are when the hormone is supplied directly.

Prescribed, never simply supplied

A licensed provider reads your history, decides whether this blend fits it, and sets the protocol.

In brief.

Two peptides share this vial, and they are not doing the same job. CJC-1295 is an analog of growth-hormone-releasing hormone, the signal the hypothalamus already sends to the pituitary gland. Ipamorelin works on a different receptor entirely — the one ghrelin uses. Neither supplies growth hormone; both are studied for prompting the body to release its own.

Promise offers the blend one way only. A licensed provider reviews your health history and prescribes it only when treatment is appropriate for you.

What is in the vial

CJC-1295 is built from the first 29 amino acids of growth-hormone-releasing hormone — the active fragment of the natural signal — with substitutions that slow the enzymes that would otherwise clear it within minutes. The form used in this kind of blend is the short-acting one, without the drug affinity complex that tethers the peptide to albumin and stretches its activity across days. That distinction matters more than it sounds, because the short-acting version is studied specifically for leaving the natural pulse pattern intact.

Ipamorelin is a five-amino-acid growth hormone secretagogue that binds the ghrelin receptor in the pituitary and hypothalamus. It drew research attention for being selective: in published work it moved growth hormone with comparatively little movement in cortisol and prolactin, which was the practical drawback of the earlier secretagogues it followed.

Why the two are studied together

The pituitary cells that make growth hormone carry both receptors, and the two run on different internal machinery. The GHRH receptor signals through the cyclic-AMP pathway, which research links to how much hormone the cell produces and holds ready. The ghrelin receptor signals through a separate calcium-dependent route, and it is also studied for easing somatostatin, the body's own brake on growth hormone release.

Pressing an accelerator while easing a brake is the mechanistic argument for pairing them, and it is why the blend is studied for a larger pulse than either peptide produces alone. What the pairing does not do is override the system. Release still runs through the pituitary, so the body's feedback controls stay in the circuit — the structural difference between a secretagogue approach and supplying growth hormone from outside. Sermorelin belongs to the same family and takes the simpler, single-peptide version of that idea.

What the research does and does not show

Both compounds have been examined in humans, mostly in short studies measuring endocrine markers — growth hormone pulses, IGF-1 — rather than long-term clinical outcomes in healthy adults. The combination is used largely on the strength of that mechanism and those short-term measures, not on the back of large trials of the blend itself.

That is worth stating plainly rather than dressing up. Interest in growth-hormone-axis peptides has run ahead of the evidence for years, and the honest description is a studied approach with a coherent rationale, not a settled one. Within hormone and organ health, Tesamorelin carries the deepest clinical literature of the group, which is one reason a provider may point you there instead.

How it is prescribed

Everything starts with the intake questionnaire written for this blend: your health history, current medications and supplements, symptoms, and what you are hoping to address. A licensed provider reads it and prescribes only when the blend is appropriate for you. Depending on what you report, they may ask for lab work before deciding.

The growth hormone axis is one where history genuinely changes the answer. Certain cancers, some pituitary conditions, and pregnancy are standard reasons a clinician declines, and a decline is a real outcome here rather than a formality.

What treatment looks like

If you are prescribed, a licensed U.S. pharmacy compounds and dispenses your medication and ships it in temperature-safe packaging. Your provider sets the protocol, timing included, because growth hormone release tracks deep sleep closely enough that when a dose lands is part of the clinical decision. Promise does not publish dosing.

Follow-up check-ins are part of the plan, so a protocol can be adjusted with a clinician involved rather than left to run on its own. The fundamentals still carry the weight they always did: sleep, training load, protein, alcohol. A peptide that works by prompting your own release is only ever as useful as the physiology doing the releasing. It is support for a promise you already made — not a substitute for keeping it.

Common questions

What is CJC-1295 / Ipamorelin?

It is a compounded blend of two peptides that act on the growth hormone axis from different directions. CJC-1295 is an analog of growth-hormone-releasing hormone, built from the active 29-amino-acid fragment of that signal and modified to resist the enzymes that clear it quickly. Ipamorelin is a five-amino-acid growth hormone secretagogue that binds the ghrelin receptor. Neither supplies growth hormone; both are studied for prompting the pituitary gland to release the body's own.

Why are CJC-1295 and ipamorelin given together?

The cells in the pituitary that produce growth hormone carry both receptors, and each receptor signals through separate internal machinery — the GHRH receptor through the cyclic-AMP pathway, the ghrelin receptor through a calcium-dependent route that is also studied for easing somatostatin, the body's brake on release. Research interest in the pairing centers on a larger pulse than either peptide produces alone, while release still runs through the pituitary and stays pulsatile.

Do I need a prescription, and how does the online visit work?

Yes, this is prescription-only. You complete the intake questionnaire written specifically for this blend, covering your health history, medications, symptoms, and goals. A licensed provider reviews it and prescribes only when treatment is appropriate for you; they may request lab work first. If you are prescribed, a licensed U.S. pharmacy compounds and ships your medication in temperature-safe packaging, with follow-up check-ins from your care team.

Is CJC-1295 / Ipamorelin FDA-approved?

No. This blend is a compounded medication and is not FDA-approved. Compounded medications are prepared by a licensed U.S. pharmacy against a prescription written for one patient, and they are not reviewed by the FDA for safety, effectiveness, or quality. A licensed provider prescribes it only after reviewing your health history.

How is it different from Tesamorelin / Ipamorelin or Sermorelin?

The secretagogue half is the same in both blends — ipamorelin, acting on the ghrelin receptor. What changes is the GHRH analog it is paired with. CJC-1295 is a modified fragment of that hormone; tesamorelin is a stabilized full-length analog with a considerably deeper human trial record, which is the practical difference between the two blends. Sermorelin is the single-peptide version of the same GHRH approach, without a secretagogue alongside it. Which of the three suits your history, if any, is your provider's call.

Related treatments

Other Hormone & Organ Health options a provider may consider.